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Abstract
Activation-induced cell death is a natural process that prevents tissue damages from over-activated immune cells. TNF-
Related apoptosis ligand (TRAIL), a TNF family member, induces apoptosis of infected and tumor cells by binding to one of
its two death receptors, DR4 or DR5. TRAIL was reported to be secreted by phytohemagglutinin (PHA)-stimulated CD4
+ T
cells in microvesicles.
We investigate here TRAIL and DR5 regulation by activated primary CD4
+ T cells and its consequence on cell death. We
observed that PHA induced CD4
+ T cell apoptosis in a dose-dependent manner. Thus, we investigated molecules involved in
PHA-mediated cell death and demonstrated that TRAIL and DR5 were over-expressed on the plasma membrane of PHA-
stimulated CD4
+ T cells. Surprisingly, DR5 was constitutively expressed in naive CD4
+ T cells at messenger RNA (mRNA) and
protein levels. Thus, using 3 dimensional microscopy and intracellular staining assays, we show that DR5 is constitutively
expressed in CD4
+ T cells and is pre-stocked in the cytoplasm. When cells are stimulated by PHA, DR5 is relocalized from
cytoplasm to plasma membrane. Small interference RNA (siRNA) and blocking antibody assays demonstrate that TRAIL/DR5
interaction is mainly responsible for PHA-mediated CD4
+ T cell apoptosis. Thus, membrane DR5 expression leading to TRAIL-
mediated apoptosis may represent one of the pathways responsible for eradication of over-activated CD4
+ T cells during
immune responses.
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Introduction
Elimination of over-activated immune cells is a natural process
that prevents autoimmunity and damages of healthy organs.
Activation–induced cell death (AICD) is one of the processes that
contribute to eliminate over-activated T cells after immune
response [1]. Apoptosis can be induced by interaction between
death ligands and their death receptors [2,3].
The Tumor Necrosis Factor (TNF) superfamily is composed by
multiple apoptotic ligands, such as FasL [4,5], tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL) [6,7,8],
and TNF-related weak inducer of apoptosis (TWEAK) [9] and
their associated-receptors. TRAIL has been shown to induce
apoptosis of the vast majority of tumor cell lines [10,11] but does
not kill normal cells [12]. This unique property is due to the fine
regulation of TRAIL-mediated apoptosis by expression of two
groups of receptors [13]. Three receptors do not induce apoptosis
(Decoy Receptors, DcR) and two activate apoptosis of target cells
(Death Receptor 4 and 5, DR4, DR5) [14,15,16]. The two
biologically active forms of TRAIL, membrane-bound (mTRAIL)
and soluble TRAIL (sTRAIL), are regulated by type I interferon
(interferon-alpha and beta: IFN-a and IFN-b) [17,18,19]. DR4-
and DR5-induced apoptosis activate the caspase pathway leading
to apoptosis of target cells through the formation of a death
inducing signaling complex (DISC) containing the death receptor
and adaptor proteins such as Fas-associated death domain
(FADD).
Previous reports showed that T cell blasts secreted bioactive
forms of TRAIL and FasL in microvesicles shortly after
Phytohemagglutinin (PHA) stimulation [20]. Following the release
of these apoptotic ligands, T cells underwent apoptosis. The same
group also demonstrated that CD8
+ T cells were more susceptible
to TRAIL regulation than CD4
+ T cells. TRAIL regulation was
defined by IL-2-dependent T cell growth in the absence of cell
death induction, characterized by cell cycle arrest in G2/M [21].
Furthermore, the authors showed that PHA-induced T cell
apoptosis was partially mediated by death receptors [22].
However, regulation of membrane expression of TRAIL death
receptors following PHA-induced CD4
+ T cell activation remains
to be determined.
We provide here some new insight concerning death receptor 5
localization and regulation in primary CD4
+ T cells. We show that
DR5 is constitutively expressed in naive CD4
+ T cells at messenger
RNA (mRNA) and protein levels. Thus, using 3 dimensional (3D)
microscopy assays, we demonstrate that DR5 is constitutively
expressed in CD4
+ T cells and is pre-stocked in the cell cytoplasm.
Furthermore, under PHA stimulation, DR5 is relocalized to the
plasma membrane. Small interference RNA (siRNA) and blocking
antibody assays showed that TRAIL/DR5 interaction is largely
responsible for PHA-mediated CD4
+ T cells death. In contrast,
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plasma membrane expression of DR5 but not TRAIL. Conse-
quently, this T cell activation does not lead to cell apoptosis due to
the lack of TRAIL expression. Thus, membrane DR5 expression
leading to TRAIL-mediated apoptosis may represent one of the
pathways responsible for elimination of over-activated CD4
+ T
cells during immune response.
Results
PHA induced apoptosis of primary CD4
+ T cells
Primary CD4
+ T cells were positively purified from fresh blood
(Fig. 1A) and were cultured overnight in the presence or absence of
PHA. We observed formation of pluricellular blastes in PHA-
treated wells (Fig. 1B). We next studied apoptosis of PHA-activated
CD4
+ T cells by FACS using two different markers: Annexin-V, 7-
AAD and Topro-III allowing us to discriminate between early
(Annexin-V) and late apoptosis (7-AAD, Topro-III). We first tested
several concentrations of PHA to induce T cell death overnight
(Fig. 1C). 1 mg/ml of PHA was sufficient to induce low levels of
apoptosis (15%), and 2.5 mg/ml induced more than 50% of
Annexin-V positive CD4
+ T cells. Between 2.5 mg/ml and 10 mg/
ml of PHA we observed a dose dependent induction of Annexin-V
by CD4
+ T cells. Then, we performed late marker of apoptosis
stainings (Topro-III and 7-AAD) on activated CD4
+ T cells
cultured overnight in presence of PHA at 2.5 mg/ml. PHA
induced dramatic apoptosis of CD4
+ T cells after 18 h of culture
(Fig. 1D). We observed that apoptotic cells expressing Topro-III
were also 7-AAD positive, confirming that cells were in the late
stage of apoptosis (Fig. 1E and F). In contrast, we observed that the
vast majority but not all CD4
+ T cells expressing Annexin-V were
Topro-III positive (Fig. 1E and F). Because Annexin-V is an early
marker of apoptosis, cells expressed Annexin-V before Topro-III,
which is a late marker of apoptosis. Thus, we tested whether
apoptotic cells were activated, using the CD69 T cell activation
marker. The vast majority of CD69 positive cells were also
expressing Topro-III, confirming that over-activated CD4
+ T cells
underwent apoptosis (Fig. 1G).
TNF family member expression by PHA-activated CD4
+ T
cells
We next investigated the pathway involved in PHA-mediated
apoptosis. CD4
+ T cells were tested for TRAIL, DR4, DR5,
Tweak-R and Fas expression. Overnight stimulation with PHA
induced strong cell surface expression of TRAIL, DR5 and Fas,
while DR4 and Tweak-R were not upregulated by CD4
+ T cells
(Fig. 2A).
Thus, we studied TRAIL and DR5 regulation by primary CD4
+
T cells. PHA activation had been demonstrated to induce soluble
TRAIL secretion, which participated to T cell activation [20].
CD4
+ T cells were cultured 1-to-5 days in the presence or absence
of PHA. We observed significant soluble TRAIL secretion after 2
and 5 days (Fig. 2B), while 18 h were sufficient to induce
membrane TRAIL expression (Fig. 2A). We then studied TRAIL
mRNA expression. Cells were cultured 18 h in the presence or
absence of PHA. After extraction, mRNA was quantified by
quantitative RT-PCR and expressed in ratio TRAIL/GAPDH.
PHA induced very high levels of TRAIL mRNA expression
compared to untreated CD4
+ T cells (Fig. 2C). Furthermore, we
observed a positive parallel between 7-AAD and TRAIL
expression, both increasing simultaneously with PHA concentra-
tion (Fig. 2D). It should be noted that the majority of TRAIL
expressing cells (75%) are also 7AAD positive. However, the
majority of 7-AAD positive cells are TRAIL negative (Fig. 2E).
TRAIL induces apoptosis by binding to one of its two death
receptors DR4 or DR5 [15]. DR4 was lightly upregulated by
PHA, while DR5 expression was strongly increased on CD4
+ T
cell membrane (Fig. 2A). For this reason, we focused our research
on DR5 study. mRNA study by quantitative RT-PCR revealed
that DR5 mRNA levels in CD4
+ T cells were highly increased by
PHA. Surprisingly, DR5 mRNA was also expressed in non-
activated CD4
+ T cells, suggesting a constitutive expression of
DR5 (Fig. 2F). To verify whether previous mRNA levels were
traduced into protein, we quantified by Elisa DR5 protein
expression after cells lysis. DR5 protein was increased by PHA,
and significant constitutive levels of DR5 protein was observed in
non-activated CD4
+ T cells (Fig. 2G). FACS analysis of
extracellular staining revealed that DR5 was not expressed at
the plasma membrane when low dose of PHA was used (1 mg/ml)
to stimulate CD4
+ T cells (Fig. 2H). We showed above that this
concentration was too low to induce apoptosis (Fig. 1C). In
contrast, higher dose of PHA (2.5 mg/ml) was inducing membrane
DR5 expression (Fig. 2H) and apoptosis of CD4
+ T cells (Fig. 1C).
These latest results strongly suggested that presence of DR5 was
responsible for apoptosis induction.
Finally, to link DR5 expression and CD4
+ T cell apoptosis, we
performed flow cytometry analysis. CD4
+ T cells were cultured
overnight in absence or presence of PHA (2.5 mg/ml) and cells
were stained with 7-AAD, Annexin-V and DR5 antibodies. Dot-
plots analysis revealed that the majority but not all DR5 positive
cells also expressed 7-AAD (Fig. 2I). The vast majority of DR5
expressing CD4
+ T cells also expressed 7AAD (69%66) and the
vast majority of 7-AAD expressing cells were also DR5 positive
(81%69) (Fig. 2J). This demonstrates that membrane DR5
expression is directly linked to CD4
+ T cell apoptosis.
Microscopic study of DR5 expression in CD4
+ T cells
For a complete study of DR5 expression and localization we
developed 3D microscopic experiments. Purified CD4
+ T cells
were cultured overnight in the presence or absence of PHA
(2.5 mg/ml). To visualize the nucleus, cells were stained with DAPI
and anti-CD4 antibody (red) to localize the plasma membrane.
DR5 protein (green) was detected using DR5 monoclonal
antibody. As illustrated in Figure 3A, image plane analysis showed
that CD4 (red) was homogeneously expressed and precisely
delineated CD4
+ T cell plasma membrane. Microscopic analysis
Figure 1. PHA induced Apoptosis of CD4
+ T cells. A.CD4
+ T cells were purified from PBMC from healthy donors. B. Cells were cultured 24 h in
presence of 2.5 mg/ml of PHA and observed by microscopy (206). PHA-treated cells are aggregated in multicellular blast. C. After 24 h, cells were
analyzed by FACS. CD4
+ T cells were cultured in presence or absence of increasing concentration of PHA and apoptosis was quantified by cytometry
using Annexin-V staining. D. Apoptosis of CD4
+ T cells cultured in presence or absence of 2.5 mg/ml was quantified using late (7-AAD, Topro-III)
apoptotic markers by cytometry. E. Dot plots analysis of unstimulated or PHA-activated CD4
+ T cells showing Annexin-V/Topro-III or 7AAD/Topro-III
double staining. F. Percentage of Annexin-V, 7-AAD, Topro-III expressed by CD4
+ T cells cultured in presence or absence of PHA for 24 h analyzed by
cytometry. G. CD69 activation marker and Topro-III double staining of untreated or PHA-activated CD4
+ T cells. P values (p) were determined using a
two-tailed Student’s t test comparing unstimulated versus PHA stimulation (p,0.05 one star, p,0.01 two stars, p,0.001 three stars). Data of panels
C, D, E and G are representative of 4 independent experiments.
doi:10.1371/journal.pone.0032874.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32874Figure 2. TNF family member expression by PHA-activated CD4
+ T cells. A. CD4
+ T cells from healthy donors were cultured 24 h in presence
(red histograms) or absence (solid grey histograms) of PHA (2.5 mg/ml) and were phenotyped for TRAIL, DR4, DR5, Tweak-R and Fas expressions by
FACS. B. Quantification of soluble TRAIL production by ELISA of PHA-activated CD4
+ T cells after 1, 2 and 5 days of culture. C. TRAIL mRNA
Microscopy Characterization of DR5 in T cells
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32874revealed that CD4
+ T cells from healthy donor expressed
intracellular but no or very low extracellular DR5 (green). DR5
was essentially localized in the cytoplasm, delineated by the
membrane (CD4, red) and the nucleus (DAPI, blue). DR5 was
located in close proximity to the membrane but remained in the
cytoplasmic compartment (Fig. 3A). This result confirmed that
DR5 is constitutively expressed in resting CD4
+ T cells as mRNA
experiments suggested (Fig. 2E). Microscopy images clearly show
that PHA-activated CD4
+ T cells expressed high levels of DR5
protein at their CD4-delineated membrane (Fig. 3A), consistent
with FACS analysis (Fig. 2A and F).
To better visualize DR5 localization in CD4
+ T cells, 3D
surface plot and 3D reconstruction analyses were performed
(Fig. 3B–C). 3D interactive surface plot using ImageJ software
allowed us to distinguish with precision the internal from external
localization of DR5 (Fig. 3B). We clearly observed that DR5
remained essentially in cytoplasm in non-activated cells, and
relocalized at the plasma membrane when stimulated by PHA. 3D
reconstruction was used to illustrate the difference of DR5
quantity between unstimulated and PHA-activated CD4
+ T cells
(Fig. 3C). 3D reconstruction represents a compilation of all images
(stacks) analyzed for one cell. This representation shows a global
view of the total quantity of each protein tested. 3D reconstruction
images revealed that PHA-stimulated cells expressed more DR5
and exhibit more colocalization with CD4 (yellow) than untreated
cells (Fig. 3C). These results were confirmed by intracellular
staining that showed higher total DR5 expression in PHA-
stimulated than in unstimulated CD4
+ T cells (Fig. 3C). 3D surface
plot and reconstruction combined analysis clearly demonstrated
that PHA-stimulated CD4
+ T cells harbored plasma membrane
DR5 expression in contrast to the restrictive intracellular DR5
expression of unstimulated CD4
+ T cells.
Finally, we quantified DR5 expression in untreated and PHA-
activated CD4
+ T cells by 3D microscopy (Fig. 4). DR5 expression
was quantified by counting the green and yellow spots (DR5 that
colocalized with CD4) in 30 untreated and 30 PHA-stimulated
cells (3 independent experiments) (Fig. 4A). We found that the
total number of DR5 spots was increased by PHA compared to
untreated cells (p=0.002) (Fig. 4B). This result is in accordance
with the increased DR5 mRNA and DR5 protein that we
previously quantified by quantitative RT-PCR and Elisa,
respectively (Fig. 2F and 2G). Furthermore, the number of DR5
spots on the membrane was also increased by PHA stimulation.
Untreated CD4
+ T cells expressed very low membrane DR5 (less
than 5% of the DR5 spots are on the membrane) contrasting with
PHA-stimulated CD4
+ T cells which expressed more than 60% of
DR5 protein on their membrane (p=0.001) (Fig. 4C).
Inhibition of PHA-mediated CD4
+ T cell apoptosis
Finally to definitively link TRAIL/DR5 expression with
CD4
+ T cell apoptosis, we inhibited the TRAIL pathway using
either the TRAIL blocker soluble DR5 (sDR5) or silencing
RNA (siRNA) techniques. Recombinant soluble DR5 is a
natural blocker of TRAIL-mediated apoptosis that binds to
soluble and/or membrane TRAIL. CD4
+ T cells were cultured
with several concentrations of PHA and in presence or absence
of sDR5 (5 mg/ml). As shown in Fig. 5A, sDR5 dramatically
reduced CD4
+ T cell apoptosis even when high doses of PHA
(5 and 10 mg/ml) were used in culture. Figure 1B clearly
showed that sDR5 at 5 mg/ml significantly inhibited induction
of Annexin-V expression by PHA-activated CD4
+ T cells
(Fig. 5B).
To better demonstrate the role of DR5 in PHA-mediated cell
death, we performed DR5 silencing mRNA (siRNA) experiments.
Freshly isolated CD4
+ T cells were transfected with scrambled or
DR5 siRNA overnight. The percentage of live transfected cells was
quantified using Alexa-488 labeled siRNA. More than 65% of
CD4
+ T cells were efficiently transfected (Fig. 5C) by scrambled
siRNA. We show that CD4
+ T cells transfected with DR5 siRNA
harbored massive downregulation of DR5 expression compared to
scrambled transfected cells (Fig. 5D). Furthermore, DR5 siRNA
transfected CD4
+ T cells become resistant to PHA-induced
apoptosis (Fig. 5E). We demonstrate here that the inhibition of
DR5 expression by siRNA dramatically reduced PHA-mediated
apoptosis confirming a central role of TRAIL/DR5 in cell death
of activated CD4
+ T cells.
Finally, we tested whether another kind of T cell activation
would induce TRAIL pathway and apoptosis. CD4
+ T cells were
stimulated using anti-CD3/CD28 antibodies. FACS analysis
revealed that anti-CD3/CD28 activation induced DR5 but not
TRAIL expression on plasma membrane of primary CD4
+ T cells.
Anti-CD3/CD28 antibodies activated the vast majority of CD4
+
T cells (70%) (Fig. 5F). However, we did not observe apoptosis
even of activated cells. T cell activation by those antibodies
induced expression of DR5 and CD69 on plasma membrane but
not TRAIL, which likely accounts for the lack of T cell apoptosis.
(Fig. 5G).
Discussion
TRAIL is a very promising candidate for immune-based
therapy due to its sophisticated way of inducing apoptosis. TRAIL
does not exhibit cytotoxic effects on normal cells and tissues [12]
and is potentially efficient to eradicate a large panel of cancer cells
[11,23]. Several clinical trials are currently evaluating TRAIL
anti-tumor effect, alone or in combination with other chemother-
apeutic drugs [24,25,26,27,28,29] [30,31]. TRAIL is also involved
in several pathologies including HIV-1 [32,33]. Indeed, plasma
TRAIL has been reported to be an early pathogenic marker in
acute HIV-1 infection and is correlated to viral load in chronic
disease [34,35]. HIV-1 upregulates DR5 expression on the
membrane of CD4
+ T cells in vitro [32,33] making them prone
quantification of unstimulated or PHA-activated CD4
+ T cells. mRNA levels were analyzed by quantitative RT-PCR. Results are expressed as the ratio of
TRAIL to GAPDH gene reporter. D. CD4
+ T cells were cultured 24 h in presence of increasing concentration of PHA. Cells were stained with 7-AAD and
membrane TRAIL (mTRAIL) antibody and were analyzed by flow cytometry. DR5 mRNA quantification of unstimulated or PHA-activated CD4
+ T cells.
E. Dot-Plot analysis of 7-AAD and mTRAIL stainings. Cells were cultured in absence or presence of PHA (2.5 mg/ml) and stained with 7-AAD and
membrane TRAIL antibody. F. mRNA levels were quantified by quantitative RT-PCR. Results are expressed as the ratio of DR5 to GAPDH gene
reporter. G. Quantification of DR5 content in PHA activated CD4
+ T cells after 24 h of culture. Cells were lysed and DR5 levels in lysates were
quantified by ELISA. H. FACS analysis of DR5 membrane expression by primary CD4
+ T cells stimulated with 1 mg/ml and 2.5 mg/ml of PHA (red
histograms) compared to untreated CD4
+ T cells (grey). I. Dot plot cytometry analysis of resting or PHA-activated CD4
+ T cells showing 7-AAD and
DR5 expression. J. CD4
+ T cells were cultured in absence or presence of PHA for 24 h. Graphics show the percentage of 7-AAD positive cells among
DR5 expressing cells under, and proportion of DR5+ among 7-AAD expressing cells. Data of panels A, D, E, H and I are representative of 4
independent experiments. P values (p) were determined using a two-tailed Student’s t test (p,0.05 one star, p,0.01 two stars, p,0.001 three stars).
doi:10.1371/journal.pone.0032874.g002
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tion of TRAIL and its receptors by human immune cells may have
important physiologic relevance.
Soluble TRAIL and soluble FasL produced in supernatants of
PHA-activated PBMC have been shown to induce apoptosis of
Jurkat T cell line [37]. Furthermore, TRAIL and FasL were
Figure 3. 3D microscopy study of DR5 expression by CD4
+ T cells. A. CD4
+ T cells were cultured overnight in presence or absence of PHA
(2.5 mg/ml) and stained for DR5 (green), nuclear staining DAPI (blue) and CD4 (red) to study DR5 protein expression and localization. Unstimulated
CD4
+ T cells exhibited DR5 protein expression in the cytoplasm at close membrane proximity, defined by CD4 staining (upper panels). In contrast,
PHA-activated CD4
+ T cells expressed intracellular and membrane DR5. DR5/CD4 colocalization appears in yellow. To better visualize DR5 localization,
a zoom of the dotted line defined zone from CD4/DR5/DAPI overlay picture was added (extreme right panels). B. DR5 analysis using 3D interactive
surface plot. Previous 3D microscopy pictures were analyzed using 3D interactive surface plot. Representation allowed a clear visualization of
intracellular DR5 (green) and membrane CD4 (red). Unstimulated CD4
+ T cells harbored only intracellular DR5 inside the CD4 (membrane)
delimitation. PHA stimulation of CD4
+ T cells induced the export of DR5 protein at the surface delineated by CD4 staining (red) but some DR5 also
remained intracellular. Yellow spots represent DR5/CD4 colocalization. C. FACS analysis of intracellular staining of DR5 and compilation of all plans
from previous microscopic images were used to perform 3D reconstruction. This representation illustrates the difference of DR5 quantity between
unstimulated and activated CD4
+ T cells. PHA-stimulated cells expressed more DR5 (green) and show more colocalization (yellow) with CD4 than
unstimulated cells. Each picture is representative of the vast majority of the observed cells on the slides.
doi:10.1371/journal.pone.0032874.g003
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compartment, but they are sometimes secreted separately. TRAIL
secretion by T cells was detected very soon after high dose of PHA
(50 mg/ml) exposure [37]. Although TRAIL secretion had been
well documented, DR5 localization and expression remained to be
clarified.
Our results show that massive cell death occurs when cells were
cultured for 24 h in presence of PHA, similar to an earlier study
[37]. We demonstrate using early and late apoptotic markers that
PHA-induced apoptosis of CD4
+ T cells was proportional to PHA
concentration. Cells that underwent apoptosis were mostly
activated cells (CD69
+). Thus, we clearly show a parallel between
activation and apoptosis.
We further investigated the pathway by which PHA-induced
apoptosis occurs. Our analysis of TNF family members revealed
that TRAIL and DR5 were highly upregulated on CD4
+ T cell
membranes compared to those of unstimulated cells. As previously
reported, CD4
+ T cells could also produce [20] soluble TRAIL
after several days in culture with PHA. However, overnight
stimulation was not sufficient to activate soluble TRAIL secretion
in contrast to membrane TRAIL, which was rapidly expressed
after stimulation. These soluble and membrane forms of TRAIL
might be differently regulated. We also tested whether the lack of
soluble TRAIL production after overnight culture could be due to
a rapid mobilization by membrane DR5 highly expressed by
activated cells. We cultured CD4
+ T cells with PHA and anti-DR5
antibodies, and measured sTRAIL production (data not shown).
The addition of DR5 blocking antibodies did not increase sTRAIL
production. Thus, the apoptosis observed after overnight PHA
activation could not be due to soluble TRAIL or soluble FasL. We
also observed that the majority but not all CD4
+ T cells expressing
DR5 were apoptotic. This could be explained by the fact that DR5
has to be expressed on plasma cell membrane and then followed
by TRAIL binding leading to apoptosis. Thus, it is not surprising
that we detected DR5-expressing cells that did not yet interact
with TRAIL-expressing cells and consequently were not into
apoptotic stage.
DR5 protein distribution in human primary cells has not been
well characterized. Therefore, our most surprising results con-
cerned DR5 expression in primary CD4
+ T cells. We show here
that DR5 mRNA and protein are constitutively expressed in
freshly purified CD4
+ T cells. Flow cytometry analysis of
intracellular DR5 staining uniquely revealed a constitutive
expression of DR5 in primary CD4
+ T cells confirming Elisa
results. This constitutive DR5 expression by human immune T
cells has not been previously described. Therefore, we developed a
3D microscopy model to better characterize DR5 protein
localization in primary CD4
+ T cells. Microcopy study revealed
that resting CD4
+ T cells expressed intracellular stock of DR5.
These results were in accordance with mRNA and Elisa data.
Death receptors are constitutively expressed and stocked in
cytoplasm of CD4
+ T cells. Thus, after cell activation DR5 could
be rapidly mobilized at the cell surface. These unexpected results
suggest that CD4
+ T cells are ‘‘programmed’’ to be eliminated by
apoptosis shortly after strong activation. In fact, we report that
DR5 is relocalized from cytoplasm to membrane under PHA
stimulation. However, it should be noticed that increased DR5
expression by PHA-stimulated CD4
+ T cells could also be due to
increased expression of total DR5 protein. Thus, PHA induces
membrane DR5 relocalization and increased of DR5 level in
Figure 4. 3D microscopy quantification of DR5 expression by CD4
+ T cells. A. CD4
+ T cells were cultured overnight in presence or absence
of PHA (2.5 mg/ml) and stained for DR5 (green), nuclear staining DAPI (blue) and CD4 (red) to study DR5 protein expression and localization. 10 cells
per experiment were quantified for their DR5 spot number in 3 independent experiments for a total of 30 cells per condition (untreated or PHA-
stimulated). White arrows show some examples of the DR5 spots that were counted B. Total number of DR5 spots in 30 untreated and 30 PHA-
stimulated cells. Results show the number of DR5 spots per cell C. Percentage of membrane DR5 expression in 30 untreated and 30 PHA-stimulated
cells. P values (p) were determined using a two-tailed Student’s t test (p,0.05 one star, p,0.01 two stars, p,0.001 three stars).
doi:10.1371/journal.pone.0032874.g004
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32874T cells. Images from microscopy show membrane expression of
DR5 and colocalization with plasma membrane CD4 after PHA
exposure.
Finally, we clearly demonstrated that TRAIL/DR5 pathway
was the major inducer of PHA-activated CD4
+ T cell apoptosis
after a short period of culture (less than 24 h). We first observed a
correlation between plasma membrane DR5 expression and levels
of apoptosis. Soluble DR5 significantly reduced CD4
+ T cells
apoptosis. To definitively link TRAIL-DR5 interaction and
apoptosis, we performed siRNA experiments. Silencing DR5
dramatically reduced PHA-mediated CD4
+ T cell apoptosis
demonstrating that TRAIL-DR5 pathway is largely involved in
PHA-induced cell death. However, it should be noted that
inhibition of the TRAIL pathway did not totally reduce cell death,
suggesting that other pathways are involved, such as Fas/FasL
[38]. Furthermore, Fas/FasL may also contributes to T cell
apoptosis after longer period of activation (48 h).
Silencing mRNA experiments also demonstrated that inhibition
of DR5 mRNA largely reduced DR5 membrane expression after
PHA stimulation. This indicates that DR5 mRNA over produc-
tion is necessary for high levels of membrane DR5 expression.
Interestingly, anti-CD3/CD28 T cell activation, which is a
more physiological stimulation than PHA, induced DR5 expres-
sion but not TRAIL on plasma membrane of CD4
+ T cells.
Consequently, we did not observe apoptosis of CD3-CD28
activated T cells. In this setting, the limiting factor is TRAIL
and not DR5. Thus, we could imagine that DR5 represents a
functional T cell activation marker, and that activated DR5
+CD4
+
T cells undergo apoptosis depending on physiological conditions.
Membrane TRAIL expression may be regulated by strong non-
physiological PHA stimulation or by type I interferon (IFN), which
are secreted by plasmacytoid dendritic cells (pDC) after viral
infection, such as HIV-1 or influenza A infection [39,40]. Thus,
apoptosis of CD4
+ T cell in viral context could be dependent on
the ability of virus to induce DR5 expression in CD4
+ T cells.
HIV-1 specifically activates CD4
+ T cells and induces DR5
membrane expression after contact of cellular CD4 and viral
gp120 [33]. In parallel, TRAIL expression is upregulated by type I
IFN produced by HIV-activated pDC, leading to TRAIL-DR5-
mediated CD4
+ T cell apoptosis [40]. The AIDS syndrome is
characterized by massive CD4
+ T cell depletion, mainly due to the
TRAIL pathway [34,41]. In contrast, influenza virus also activates
IFN-a production by pDC that induces TRAIL expression on
CD4
+ T cells [39,42]. However, influenza does not activate DR5
expression on CD4
+ T cells, and TRAIL-DR5-mediated apoptosis
of CD4
+ T cells is not observed. Thus, membrane DR5 expression
appears to be a key factor regulating the balance between primary
CD4
+ T cell apoptosis and survival.
In conclusion, we demonstrate that strong T cell activation leads
to rapid TRAIL-DR5-mediated apoptosis of human primary
CD4
+ T cells. This fast cell death could be explained by the rapid
mobilization of DR5 protein from the cytoplasm stocks, observed
in non-activated CD4
+ T cells, to the plasma cell membrane when
cells are strongly stimulated. This mechanism of activation-
induced cell death (AICD) of human primary T lymphocytes is
rapid, and thus may have physiological relevance.
Materials and Methods
Patients blood samples
Blood from 30 healthy HIV-1-seronegative blood bank donors
was obtained from ‘‘Etablissement Franc ¸ais du Sang’’ (convention
# 07/CABANEL/106), Paris, France.
Ethics Statement
Experimental procedures with human blood have been
approved by Necker Hospital Ethical Committees for human
research and were done according to the European Union
guidelines and the Declaration of Helsinki.
Isolation and culture of blood leukocytes. In vitro
experiments were performed using peripheral blood
mononuclear cells (PBMC) isolated by density centrifugation
from peripheral blood leukocyte separation medium (Cambrex,
Gaithersburg, MD). CD4
+ T cells were purified using the CD4
purification kit (Miltenyi Biotech, Bergisch Gladbach, Germany).
Cells were cultured in RPMI 1640 (Invitrogen, Gaithersburg, MD)
containing 10% fetal bovine serum (Hyclone, Logan, UT) and 1%
Pen-Strep-Glut (Invitrogen).
PHA stimulation. CD4
+ T cells from healthy donors were
seeded at 50,000 cells per 100 ml and cultured overnight with
several PHA concentrations (ranging form 0.1 to 10 mg/ml). T cell
activator anti-CD3 and anti-CD28 (BD Biosciences, San Jose, CA)
antibodies were coated 1 h at 37uC in PBS 16 on plastic wells
were used to activate CD4
+ T cells. Supernatants were collected
for cytokine detection and cells were used for flow cytometry
(FACS) experiments.
Apoptosis assay. After 24 h of culture with PHA, purified
CD4
+ T cells were washed with Annexin buffer (BD Bioscience)
and incubated 15 minutes with Annexin-V (BD Bioscience),
Topro-III (Invitrogen) and 7-ADD (BD Bioscience) at 4uC.
Soluble recombinant DR5 (Myltenyi) was used at several
concentration (0.1–10 mg/ml) to block PHA-induced apoptosis.
Apoptosis was quantified and analyzed by multicolor flow
cytometry.
Flow cytometry. CD4
+ T cells were incubated for 20 min at
4uC with Vioblue-conjugated anti-CD4 (Miltenyi), FITC-DR5
(eBioscience, San Diego, CA), PE-TRAIL (eBioscience), Tweak-R-
PE (R&D system), Fas-APC (BD Bisoscience), CD69-FITC (BD
Bioscience) or with appropriate isotype-matched control
antibodies (at 5 mg/mL each) in PBS containing 2% mouse
Figure 5. Apoptosis inhibition of CD4
+ T cells by soluble DR5 and DR5 siRNA. A. CD4
+ T cells were cultured 24 h in presence of increasing
concentration of PHA and with or without 5 mg/ml of DR5. Apoptosis was quantified using Annexin-V staining by flow cytometry. B. CD4
+ T cells
were cultured 24 h in presence of 5 mg/ml of PHA and with or without soluble DR5 (5 mg/ml). Apoptosis was quantified using Annexin-V staining by
flow cytometry. C. Efficiency of siRNA transfection in CD4
+ T cells. Cells were transfected with unlabelled or Alexa-488 scrambled siRNA overnight. Dot
plots show transfection efficiency of CD4
+ T cells by Scr-Alexa-488 siRNA (right panel). D. Transfection of CD4
+ T cells with DR5 siRNA significantly
inhibited DR5 expression by PHA-stimulated CD4
+ T cells in contrast to scrambled (Scr) siRNA (left panel). Inhibition of DR5 expression at the surface
of PHA-stimulated CD4
+ T cells using DR5 siRNA also dramatically inhibited Annexin-V positive cells induced by PHA compared to Scr siRNA (right
panel). E. Dot plot analysis of untransfected and transfected CD4
+ T cells with scrambled siRNA (Scr siRNA), DR5 siRNA (DR5 siRNA). After overnight
transfection, CD4
+ T cells were cultured in absence (upper panels) or presence (lower panels) of PHA. Images show dot plots of DR5/Annexin-V
staining. F. TRAIL, DR5 and CD69 FACS analysis by CD4
+ T cells stimulated overnight in presence of anti-CD3 and anti CD28 antibodies. G. FACS dot
plot analysis of CD69-Annexin-V and CD69-Topro-III staining of CD4
+ T cells cultured in presence or absence of anti-CD3/CD28 activation overnight.
Data of panels C, D, E, F and G are representative of 4 independent experiments. P values (p) were determined using a two-tailed Student’s t test
(p,0.05 one star, p,0.01 two stars, p,0.001 three stars).
doi:10.1371/journal.pone.0032874.g005
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cold PBS-FBS 2% and FACS analysis was performed on a
FACSCanto 7 colors flow cytometer using FACSDiva software
(BD Biosciences). FlowJo software (Treestar, Ashland, OR) was
used to analyze flow cytometry data.
Cytokine detection. Purified CD4
+ T cells were cultured in
presence or absence of PHA from 1 to 5 days. Supernatants were
collected and tested for their soluble TRAIL content using TRAIL
ELISA kit (Diaclone). For DR5 protein quantification, stimulated
or non stimulated CD4
+ T cells were cultured overnight and total
cells were lysed. Lysate DR5 content were quantified using DR5
Elisa Kit (Invitrogen).
siRNA T cell transfection. CD4
+ T cells were seeded at 10
5
cell/100 ml in96wellplatesand incubatedat37uC.3 mlofHi pe rf ec t
transfection reagent (Qiagen, Valencia, CA) were added to
appropriate siRNA concentration and adjusted at 100 ml with
serum-free medium. Then, the solution was gently mixed and
incubatedatroomtemperatureduring30 minutes.Afterincubation,
the mix was added to cells in culture. Finally, cells were incubated at
37uC overnight with or without PHA (2.5 mg/ml). Control was
performed using scrambled siRNA and transfection efficiency was
tested by FACS using Alexa-488 tagged scrambled siRNA (all from
Qiagen). Apoptosis was determined using Annexin-V staining and
analyzed by flow cytometry.
RNA extraction. 500 mL of Trizol were added to the pellet of
CD4
+ T cells the cells were then mixed during 1 minute and
incubated at room temperature during 5 min. 100 mLo f
chloroform were added and the mix were centrifuged at
13 000 rpm during 15 min. The upper phase were recovered
and 500 mL of isopropanol were added and mixed during 1 hour
at 4uC. The mix were then centrifuged during 10 min at
13 000 rpm. 500 mLo f7 5 uC ethanol were added to the pellets
after isopropanol were removed (13 000 rpm during 15 min).
Finally, the pellets were recovered in H20-DEPC. The RNA were
stored at 280uC.
Reverse transcription. The quantity of RNA was dosed and
1 mg of RNA per sample was used to perform the reverse
transcription. We prepared mix of 12 mL including the mRNA,
hexa-primers and H20-DEPC. The samples were incubated at
65uC during 5 mins. A mix containing 56Buffer, dNTP Mix, RT
enhancer and Verso Enzyme was prepared (Verso cDNA Kit,
Thermo Fisher Scientific, abgene, UK). The samples were
incubated 5 min at room temperature, 1 hour at 42uC and then
2 min at 95uC.
PCR. Expression of DR5 gene by CD4
+ T cells was
developed. Primers were synthesized by Invitrogen (primer DR5
sens 59 AGGTGAAGTGGAGCTAAGTC 39, DR5 antisens: 59
TCACTCCAGGGTGTACAATC 39; primer b2-microglobuline
sens: 59 CCAGCAGAGAATGGAAAGTC, b2-microglobuline
antisens GATGCTGCTTACATGTCTCG). Amplification
reaction were realized with a Mastercycler Eppendorf machine
according to the following program (Tm 55uC): Lid 110uC, 5 min
at 94uC, 1 min at 55uC and 1 min 30 at 72uC, 1 min at 94uC (35
cycles) and finally 10 min at 72uC. Samples were run on an
eletrophoresis gel agarose 1% during 2 h at 80 V. The threshold
level was determined by the software according to the optimization
of the standard curve. Arbitrary quantity values were assigned to
the resulting standard and 4-fold serial dilutions were made to
obtain 8-point standard curve. Results are presented as ratios
between the target gene and the GAPDH mRNA.
Three-dimensional microscopy. Purified CD4
+ T cells
were cultured overnight in presence of PHA. CD4
+ T cells were
plated on poly-L-lysine (Sigma)-coated slides and then fixed in 4%
paraformaldehyde, quenched with 0.1 M glycine. Cells were
incubated in permeabilizing buffer containing 1% saponin with
mAb DR5 (ebioscience) and with Alexa547 labeled anti-CD4 (BD
bioscience). DR5 staining was revealed by a goat anti-mouse IgG-
Alexa488 (Jackson ImmunoResearch, West Grove, PA). Nucleus
was stained using DAPI (Molecular Probes, Paisley, UK).
Mounted slides were scanned with a Nikon Eclipse 90i Upright
microscope (Nikon Instruments Europe, Badhoevedorp, The
Netherlands) using a 1006 Plan Apo VC piezo objective (NA
1.4) and Chroma bloc filters (ET-DAPI, ET-GFP) and were
subsequently deconvoluted with a Meinel algorithm and 8
iterations and analyzed using MetamorphH (MDS Analytical
Technologies, Winnersh, UK). DR5/CD4/DAPI/Overlay/
Confocal plane: Representative 2D focal plan. XZ/YZ view of
Confocal plane: XZ/YZ projection of the XY focal plan along the
red cross axis. Overlay with bright: DIC. Reconvolution overlays:
2D projections of the maximum intensity pixels along the Z axis.
3D: 3D reconstruction analysis of the total cell using the ImageJ64
software (NIH, Bethesda, MD, USA).
Statistical analysis. Experiments were repeated at least four
times. P values (p) were determined using a two-tailed Student’s t
test. p,0.05 was considered statistically significant. Unvaried
distributions of flow cytometric data were performed by
probability binning, in 300 bins using FlowJo software [43].
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